A Multidimensional approach to protecting the World’s Health
Introduction to Viracorp
More than a year later, new strains are emerging at an increasing rate, and vaccines provide variable immunity against these emerging variants, needing multifaceted approaches to control the pandemic.
Despite the work that’s already been put in to slow the spread of CoVID-19, there is still much to do and experts predict this could remain a global pandemic for an unforeseeable time before it is controlled to an endemic level globally.
Our scientists and politicians have spent immense time and money to produce solutions for the world but we’re still finding that protective tools like PPE aren’t keeping people safe enough, and tests for CoVID-19 and other viruses aren’t returning an accurate result fast enough. What’s more, vaccines simply can’t reach people in countries that are in dire need due to how vaccines must be transported and stored.
Prof. Muhammad Munir
Chief Scientific Officer
A multi-faceted approach to protecting the World’s health.
ViraCorp & Subsidiaries
ViraCorp through its subsidiaries are a group of biomedical research and development companies, on a mission to improve the health outcomes for as many of the world’s population as possible.
Specifically focusing on protecting and preventing the disastrous humanitarian and economic impacts of viral outbreaks, pandemics and endemic infections, ViraCorp is taking an innovative, disruptive approach to developing viral defence products.
ViraCorp has a formidable combination of unique Intellectual Property, world-class Researchers and facilities, and a multidisciplinary, seasoned Management Team that uniquely position it for success.
Three pillars of protection
ViraCorp is a multifaceted holding company that provides corporate governance, strategic management and pooled resource support to its subsidiaries in various biotechnology and medical verticals. ViraCorp also engages actively in philanthropy and humanitarian support via a number of foundations and charitable organisations.
A next-generation, intranasal, recombinant vectored vaccine against COVID-19 that reduces transmission and addresses other primary risks and shortfalls of other vaccines in the market.
A diagnostic testing platform for SARS-CoV-2 and other respiratory viruses. ViraCheck’s apparatus can detect up to 6 different pathogens in a single test. The system has been refined to be highly effective in obtaining an accurate result within 15 minutes of taking a sample.
A patented Virucidal, Antiviral & Antimicrobial coating (Neutrapodal™ Technology) which has been scientifically demonstrated to have profound antiviral properties against SARS-CoV-2 (including new strains), Influenza (PR8 strain), and Bacteria (E. coli).